ng28ÄϹ¬Öêʽ»áÉçÐû²¼£¬½«ÔÚµÚ16½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©Äê»áÉÏÐû²¼Æä°¢¶û´Äº£Ä¬²¡£¨AD£©ÖÎÁÆÒ©ÎïLEQEMBI?£¨lecanemab-irmb£©100 mg/mLµÄIIIÆÚClarity ADÑо¿µÄ×îÐÂÊý¾ÝÒÔ¼°ÕýÔÚ¿ª·¢µÄƤÏÂÖƼÁµÄÐÂÊý¾Ý£¬¸Ã¼¯»á½«ÓÚ2023Äê10ÔÂ24ÈÕÖÁ27ÈÕÔÚÃÀ¹úÂíÈøÖîÈûÖݲ¨Ê¿¶Ù¾ÙÐС£¼¯»áÉÏ£¬³ýÁ˽éÉÜng28ÄϹ¬LEQEMBIµÄÊý¾ÝÍ⣬»¹½«½éÉÜE2511£¨Ò»ÖÖÑо¿ÐÔÔ¼¡ÇòÂÑ°×ÊÜÌ弤øA£¨TrkA£©ÑôÐԱ乹µ÷Àí¼Á£¨PAM£©£©µÄIÆÚÊý¾ÝÒÔ¼°¹«Ë¾AD²úÆ·ÏßµÄÆäËüÑо¿¡£Ôڴ˴μ¯»áÉÏ£¬ng28ÄϹ¬½«Í¨¹ýÎ峡¿ÚÍ·±¨¸æºÍÊ®³¡º£±¨Õ¹Ê¾À´½éÉÜÊý¾ÝºÍÑо¿½á¹û¡£BioArctic ½«¾Í lecanemab ×÷¿ÚÍ·±¨¸æ¡£
×îÐÂרÌâÑÐÌÖ»á4¡ª¡ªLecanemabÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡£ººã¾ÃÁÆЧ¡¢Ô¤²âÐÔÉúÎï±ê¼ÇÎïºÍÐÂÐÍƤϸøÒ©
ng28ÄϹ¬Éñ¾ÄÚ¿ÆÁÙ´²Ñо¿¸ß¼¶¸±×ܲá¢ÁÙ´²Ö¤¾ÝÉú³É²¿¸±Ê×ϯÁÙ´²¹ÙMichael Irizarryҽѧ²©Ê¿ÌåÏÖ£¬”°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øÐÔµÄÍç¹Ì¼²²¡£¬ÐèÒªÔçÆÚÕï¶ÏºÍÁ¬ÐøÖÎÁÆ¡£LEQEMBIÄܹ»Çå³ý¸ß¶¾ÐÔÔÏËά£¬´Ó¶øÖ§³Ö°¢¶û´Äº£Ä¬²¡µÄÉñ¾Ôª¹¦Ð§£¬¶ø¸ß¶¾ÐÔÔÏËάÔÚ°ß¿é±»Çå³ýºóÈÔ»á¼ÌÐøµ¼ÖÂÉñ¾ÔªËðÉ˺ÍËÀÍö¡£ÎÒÃÇÆÚ´ýÔÚ2023ÄêCTADÉÏ·ÖÏíеÄLEQEMBIµÍtauÑÇ×éÊý¾ÝºÍƤÏÂ×¢ÉäÊý¾Ý¡£”
ÆäËüÖ÷Òª¿ÚÍ·±¨¸æ°üÀ¨
ng28ÄϹ¬Ñݽ²ÁбíÈçÏÂ:
±¾ÐÂΟåÌÖÂÛÁËÒ©ÎïÔÚ¿ª·¢ÖÐÑо¿ÐÔÓÃ;£¬²¢·Çת´ï¹ØÓÚÁÆЧºÍÄþ¾²ÐԵĽáÂÛ£¬²»°ü¹ÜÈκÎÑо¿ÐÔÒ©ÎォÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃÒ©Æ·¼à¹Ü»ú¹¹Åú×¼¡£
MEDIA CONTACTS: Eisai Co., Ltd. Public Relations Department TEL: +81 (0)3-3817-5120
Eisai Inc. (U.S.) Libby Holman + 1-201-753-1945 Libby_Holman@Eisai.com
Eisai Europe, Ltd. (UK, Europe, Australia, New Zealand and Russia) EMEA Communications Department +44 (0) 786 601 1272 EMEA-comms@eisai.net